Eileen Brown

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
    Eileen Brown
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 12:773-82. 2009
  2. ncbi A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
  3. ncbi Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
  4. ncbi Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004
  5. ncbi Clinical relevance of depressive symptom improvement in bipolar I depressed patients
    Doug Williamson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Affect Disord 92:261-6. 2006
  6. ncbi Acute dysphoric mania: treatment response to olanzapine versus placebo
    Robert W Baker
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 23:132-7. 2003
  7. ncbi Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial
    Cherri Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:417-33. 2002
  8. ncbi Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
  9. ncbi Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
  10. ncbi Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study
    John H Heiligenstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:207-17. 2006

Detail Information

Publications18

  1. ncbi Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
    Eileen Brown
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Int J Neuropsychopharmacol 12:773-82. 2009
    ..There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia...
  2. ncbi A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression
    Eileen B Brown
    Lilly Research Laboratories, Indianapolis, IN, USA
    J Clin Psychiatry 67:1025-33. 2006
    ..Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine...
  3. ncbi Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  4. ncbi Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004
    ..Few controlled studies examine the treatment of depressive features in mania...
  5. ncbi Clinical relevance of depressive symptom improvement in bipolar I depressed patients
    Doug Williamson
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
    J Affect Disord 92:261-6. 2006
    ..Gaps remain between rating scale changes obtained in a clinical trial and what those results mean in clinical practice...
  6. ncbi Acute dysphoric mania: treatment response to olanzapine versus placebo
    Robert W Baker
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Psychopharmacol 23:132-7. 2003
    ..Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms...
  7. ncbi Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial
    Cherri Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 24:417-33. 2002
    ..Because the symptoms of premenstrual dysphoric disorder (PMDD) are limited to the luteal phase of the menstrual cycle, the potential benefit of luteal-phase dosing has been hypothesized...
  8. ncbi Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
    ..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes...
  9. ncbi Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study
    Ferenc Martenyi
    Lilly Research Laboratories, Vienna, Austria
    J Clin Psychopharmacol 27:166-70. 2007
    ..9), and -36.6 (25.7) in the 20-mg fluoxetine, 40-mg fluoxetine, and placebo arms, respectively. Placebo response rate was substantially higher in this study than in a previously published fluoxetine trial of posttraumatic stress disorder...
  10. ncbi Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study
    John H Heiligenstein
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 16:207-17. 2006
    ....
  11. ncbi Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
    Stephen K Brannan
    Cyberonics, Houston, TX 77058, USA
    J Psychiatr Res 39:43-53. 2005
    ..Improvements in pain severity occurred independently of changes in depressive symptom severity...
  12. ncbi Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine
    Melissa J Joliat
    J Clin Psychopharmacol 24:464-7. 2004
  13. ncbi Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment
    Teri Pearlstein
    Women's Behavioral Health Program, Women and Infants Hospital, Providence, RI 02905-2499, USA
    Am J Obstet Gynecol 188:887-95. 2003
    ..The rapid recurrence of symptoms further supports the view of premenstrual dysphoric disorder as a clinical entity distinct from depression...
  14. ncbi Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
    Ferenc Martenyi
    Novartis Pharmaceuticals, Basel, Switzerland
    Br J Psychiatry 181:315-20. 2002
    ..027). There were no clinically significant differences in treatment-emergent adverse events between treatment groups. CONCLUSIONS: Fluoxetine is effective and well tolerated in the prevention of PTSD relapse for up to 6 months...
  15. ncbi Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy
    Stephanie C Koke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Am J Obstet Gynecol 187:551-5. 2002
    ....
  16. ncbi Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression
    Cherri M Miner
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA
    J Clin Psychiatry 63:232-40. 2002
    ....
  17. ncbi Fluoxetine versus placebo in posttraumatic stress disorder
    Ferenc Martenyi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind. 46285, USA
    J Clin Psychiatry 63:199-206. 2002
    ..CONCLUSION: Fluoxetine is effective and well tolerated in the treatment of PTSD. Most PTSD patients will respond satisfactorily at doses in the upper normal range for the usual antidepressant doses of fluoxetine...
  18. ncbi Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents
    Mary Nilsson
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Child Adolesc Psychopharmacol 14:412-7. 2004
    ..During treatment with fluoxetine, the growth of child and adolescent patients should be monitored...